Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results

被引:87
作者
Veit, P
Antoch, G
Stergar, H
Bockisch, A
Forsting, M
Kuehl, H
机构
[1] Univ Hosp Essen, Dept Diagnost & Intervent Radiol, D-45122 Essen, Germany
[2] Univ Hosp Essen, Dept Nucl Med, D-45122 Essen, Germany
关键词
positron emission tomography/computed tomography; radiofrequency ablation; postinterventional surveillance; metastases; residual tumor;
D O I
10.1007/s00330-005-2767-0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The aim of this study was to determine the accuracy of dual-modality positron emission tomography(PET)/computed tomography (CT) in the detection of residual tumor after radiofrequency ablation (RFA) of liver metastasis of colorectal cancer. Eleven patients with 16 hepatic metastases (mean size 2.9 cm) from colorectal cancer were enrolled in this study, and 19 RFA procedures and 32 PET/CT examinations were performed. The patients had PET/CT before and after RFA using [F-18]-2-fluoro-2-deoxy-D-glucose. CT images alone were read by two radiologists, PET images alone were evaluated by two nuclear physicians. Fused images were read by one physician of each speciality in consensus. The accuracy for detection of residual tumor by the different imaging modalities following RFA was assessed. Eleven patients with a mean age of 63 (range 55-71) years were evaluated. The mean follow-up period was 393 days. The overall procedure-based sensitivity for detection of residual tumor was 65% for PET and PET/CT and 44% for CT alone. The accuracies were 68% and 47%, respectively. Four patients had residual tumor after RFA, six patients total developed local recurrence. PET/CT therefore possibly proved superior to CT alone when assessing the liver for residual tumor after RFA.
引用
收藏
页码:80 / 87
页数:8
相关论文
共 40 条
[1]   FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation [J].
Anderson, GS ;
Brinkmann, F ;
Soulen, MC ;
Alavi, A ;
Zhuang, HM .
CLINICAL NUCLEAR MEDICINE, 2003, 28 (03) :192-197
[2]   Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: Introduction and evaluation [J].
Antoch, G ;
Kuehl, H ;
Kanja, J ;
Lauenstein, TC ;
Schneemann, H ;
Hauth, E ;
Jentzen, W ;
Beyer, T ;
Goehde, SC ;
Debatin, JF .
RADIOLOGY, 2004, 230 (03) :879-885
[3]   Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology [J].
Antoch, G ;
Vogt, FM ;
Freudenberg, LS ;
Nazaradeh, F ;
Goehde, SC ;
Barkhausen, J ;
Dahmen, G ;
Bockisch, A ;
Debatin, JF ;
Ruehm, SG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (24) :3199-3206
[4]   Non-small cell lung cancer: Dual-modality PET/CT in preoperative staging [J].
Antoch, G ;
Stattaus, J ;
Nemat, AT ;
Marnitz, S ;
Beyer, T ;
Kuehl, H ;
Bockisch, A ;
Debatin, JF ;
Freudenberg, LS .
RADIOLOGY, 2003, 229 (02) :526-533
[5]  
Antoch G, 2004, J NUCL MED, V45, p56S
[6]   Whole-body positron emission tomography-CT: Optimized CT using oral and IV contrast materials [J].
Antoch, G ;
Freudenberg, LS ;
Stattaus, J ;
Jentzen, W ;
Mueller, SP ;
Debatin, JF ;
Bockisch, A .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2002, 179 (06) :1555-1560
[7]   Value of CT volume imaging for optimal placement of radiofrequency ablation probes in liver lesions [J].
Antoch, G ;
Kuehl, H ;
Vogt, FM ;
Debatin, JF ;
Stattaus, J .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2002, 13 (11) :1155-1161
[8]  
BALLANTYNE GH, 1993, CANCER, V71, P4252, DOI 10.1002/1097-0142(19930615)71:12+<4252::AID-CNCR2820711815>3.0.CO
[9]  
2-6
[10]  
Bar-Shalom R, 2003, J NUCL MED, V44, P1200